Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are being processed within 1 distinct art unit, indicating a consistent technical focus for the company's current patent applications. This concentration in 1 distinct art unit suggests that the company is pursuing multiple related inventions within a specific pharmaceutical niche.
The prosecution involves 2 distinct examiners, meaning each of the 2 pending office actions is being reviewed by a different person. KATAKAM, SUDHAKAR is identified as the busiest examiner, responsible for 1 busiest examiner pending action. This reflects an even split of the workload, as the other pending action is handled by the other distinct examiner.
The use of 2 distinct examiners within 1 distinct art unit for 2 pending office actions presents a unique situation for practitioners. While the technical standards of the art unit remain constant, the company must address the individual preferences of 2 different examiners. This requires a strategy that balances consistency in the Biotechnology & Pharmaceuticals field with the specific feedback from KATAKAM, SUDHAKAR and the other examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | NIEBAUER, RONALD T | 60d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | NIEBAUER, RONALD T | 60d |
| 18725112 | Application of Polypeptide in Preparation of Product for Preventing or Treating Skin Injury Diseases | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725112 | Application of Polypeptide in Preparation of Product for Preventing or Treating Skin Injury Diseases | KATAKAM, SUDHAKAR | 1658 | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | NIEBAUER, RONALD T | 1658 | §101§102§112 | Non-Final OA | 60d | Pending | Jul 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Gooddoctor Panxi Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Sudhakar Katakam has the most, with 1 of Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
